Author

Peter Bossuyt

Charting the path ahead in UC: A patient-centred approach to evidence-driven care (AbbVie) (Complete Session)
Charting the path ahead in UC: A patient-centred approach to evidence-driven care (AbbVie) (Complete Session)

Peter Bossuyt  et al.

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

ULTRAPROACTIVE THERAPEUTIC DRUG MONITORING BASED ON POINT-OF-CARE TESTING OF INFLIXIMAB IS NOT SUPERIOR TO REACTIVE DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 1 YEAR RESULTS OF A PRAGMATIC CLINICAL TRIAL
ULTRAPROACTIVE THERAPEUTIC DRUG MONITORING BASED ON POINT-OF-CARE TESTING OF INFLIXIMAB IS NOT SUPERIOR TO REACTIVE DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 1 YEAR RESULTS OF A PRAGMATIC CLINICAL TRIAL

Peter Bossuyt  et al.

SCORING OF HISTOLOGICAL REMISSION IN ULCERATIVE COLITIS BASED ON AUTOMATED COMPUTER-AIDED ANALYSIS OF ENDOSCOPIC IMAGES OUTPERFORMS HUMAN SCORING
SCORING OF HISTOLOGICAL REMISSION IN ULCERATIVE COLITIS BASED ON AUTOMATED COMPUTER-AIDED ANALYSIS OF ENDOSCOPIC IMAGES OUTPERFORMS HUMAN SCORING

Peter Bossuyt  et al.

Targeting IL-23: emerging possibilities in the management of Crohn’s disease (AbbVie) - Getting a measure on the true impact of Crohn’s disease
Targeting IL-23: emerging possibilities in the management of Crohn’s disease (AbbVie) - Getting a measure on the true impact of Crohn’s disease

Peter Bossuyt

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Fistulising CD / Fistulising CD: Assess, treat, error
Fistulising CD / Fistulising CD: Assess, treat, error

Peter Bossuyt  et al.

Teams and tools to enable effective early management of IBD
Teams and tools to enable effective early management of IBD

Peter Bossuyt

THE VARIABILITY IN THE DISTRIBUTION OF HISTOLOGICAL ACTIVITY IN COLONIC SEGMENTS IN PATIENTS WITH ULCERATIVE COLITIS AND THE IMPACT HEREOF ON THE DEVELOPMENT OF AI TOOLS
THE VARIABILITY IN THE DISTRIBUTION OF HISTOLOGICAL ACTIVITY IN COLONIC SEGMENTS IN PATIENTS WITH ULCERATIVE COLITIS AND THE IMPACT HEREOF ON THE DEVELOPMENT OF AI TOOLS

Peter Bossuyt  et al.

HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)
HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)

Peter Bossuyt  et al.

AN AUTOMATED SYSTEM FOR ESTIMATION OF HISTOLOGICAL DISEASE ACTIVITY IN ULCERATIVE COLITIS: COMPARISON OF PERFORMANCES WITH WHITE LIGHT VERSUS SINGLE WAVELENGTH ENDOSCOPY
AN AUTOMATED SYSTEM FOR ESTIMATION OF HISTOLOGICAL DISEASE ACTIVITY IN ULCERATIVE COLITIS: COMPARISON OF PERFORMANCES WITH WHITE LIGHT VERSUS SINGLE WAVELENGTH ENDOSCOPY

Peter Bossuyt  et al.

Can we rely on clinical assessment for long-term monitoring? Yes and no
Can we rely on clinical assessment for long-term monitoring? Yes and no

Peter Bossuyt  et al.

MAINTENANCE OF CLINICAL, ENDOSCOPIC, AND BIOMARKER IMPROVEMENTS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF THE PHASE 3 U-ENDURE STUDY
MAINTENANCE OF CLINICAL, ENDOSCOPIC, AND BIOMARKER IMPROVEMENTS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF THE PHASE 3 U-ENDURE STUDY

Peter Bossuyt  et al.

52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION
52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION

Peter Bossuyt  et al.

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Peter Bossuyt  et al.

COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY
COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY

Peter Bossuyt  et al.

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Peter Bossuyt  et al.

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES
AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Peter Bossuyt  et al.

EFFECT OF 104 WEEKS OF MIRIKIZUMAB TREATMENT ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
EFFECT OF 104 WEEKS OF MIRIKIZUMAB TREATMENT ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Peter Bossuyt  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Peter Bossuyt  et al.

Item 1 - 20 / 22
1
2